• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Aldara gets FDA nod for treatment of sBCC

Article

St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).

Recent Videos
Related Content
Study Compares Dose Escalation with Biologics in Psoriasis

Study Compares Dose Escalation with Biologics in Psoriasis

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
Publishing Excellence Runs More Than Skin Deep

Publishing Excellence Runs More Than Skin Deep

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Oral Zasocitinib Demonstrates Safety and Efficacy in Moderate to Severe Plaque Psoriasis

Oral Zasocitinib Demonstrates Safety and Efficacy in Moderate to Severe Plaque Psoriasis

Article
Derm In The News: September 1-7

Derm In The News: September 1-7

Article
© 2024 MJH Life Sciences

All rights reserved.